HOTH - Hoth Therapeutics expands license agreement to include innovative cancer treatment

Hoth Therapeutics (HOTH) expands its licensing agreement from North Carolina State University to include the worldwide development and commercialization of treatments targeting mast cell derived cancers and anaphylaxis. The HT-KIT drug is designed to more specifically target the receptor tyrosine kinase KIT in mast cells, which is required for the proliferation, survival and differentiation of bone marrow-derived hematopoietic stem cells."We are delighted to expand this strategic alliance with NC State and our Scientific Advisory Board member, Dr. Glenn Cruse. We believe that the HT-KIT pathway is a promising novel target for combating both mast cell-derived cancers and mast cell-mediated anaphylaxis. This expanded license agreement highlights the broad potential of our diverse pipeline that is aimed at meeting critical unmet patient needs and further supports Hoth's strategy to build a sustainable therapeutics company that is patient focused." said Robb Knie, CEO.

For further details see:

Hoth Therapeutics expands license agreement to include innovative cancer treatment